Lexicon Pharmaceuticals Inc has 4 Schedule 13D or 13G filings on record since 2025-07-08. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Invus Global Management, LLC | 39.4% | 42,765,057 | SCHEDULE 13D/A, 2026-05-08 | 2026-04-30 |
| Fmr LLC | 11.7% | 51,782,045 | SCHEDULE 13G/A, 2026-08-06 | 2026-06-30 |
Purpose of Transaction (Item 4)
Invus Global Management, LLC
Item 4 of the Statement is hereby amended and supplemented as follows: As previously disclosed in Amendment No. 25, on February 2, 2026, Artal Participations S.a.r.l. acquired 367,145.12 shares of Preferred Stock, and on February 17, 2026 Artal Participations S.a r.l. purchased an additional 41,289.58 shares of Preferred Stock, in each case, pursuant to the terms of the Preferred Purchase Agreement. Each share of Preferred Stock would automatically convert into 50 shares (subject to adjustments) of Issuer Common Stock immediately following the satisfaction of all of the following conditions: (i) the approval of the New Charter by the shareholders of the Issuer at the Annual Meeting; (ii) the adoption of the New Charter by the Issuer's board of directors; and (iii) the filing and acceptance of the New Charter with and by the Secretary of State of the State of Delaware. On April 30, 2026, all conditions were met, and the 408,434.70 shares of Preferred Stock directly held by Artal Participations S.a.r.l. automatically converted into 20,421,735 shares of Issuer Common Stock.Item 4 of the SCHEDULE 13D/A filed 2026-05-08
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-08 | Fmr LLC | 10.5% | SCHEDULE 13G/A |
| 2026-02-02 | Invus Global Management, LLC | 36.2% | SCHEDULE 13D/A |
| 2026-05-08 | Invus Global Management, LLC | 39.4% | SCHEDULE 13D/A |
| 2026-08-06 | Fmr LLC | 11.7% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Lexicon Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.